Irlanda - anglès - HPRA (Health Products Regulatory Authority)

fresenius medical care nephrologica deutschland gmbh - paricalcitol - solution for injection - 5 microgram/ml

Estats Units - anglès - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

Israel - anglès - Ministry of Health

unipharm ltd, israel - paricalcitol - solution for injection - paricalcitol 0.005 mg / 1 ml - paricalcitol - paricalcitol is indicated in adults for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure who are undergoing haemodialysis.

Israel - anglès - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules - paricalcitol 1 mcg - paricalcitol - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Israel - anglès - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Estats Units - anglès - NLM (National Library of Medicine)

cardinal health - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 1 ug

Estats Units - anglès - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug - zemplar capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. zemplar capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). zemplar capsules should not be given to patients with evidence of - hypercalcemia or - vitamin d toxicity [see warnings and precautions ( 5.1 )] .   risk summary limited data with zemplar capsules in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalc

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

fresenius medical care nephrologica deutschland gmbh - paricalcitol - solution for injection - 2 microgram/ml

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

fresenius medical care nephrologica deutschland gmbh - paricalcitol - solution for injection - 5 microgram/ml

Israel - anglès - Ministry of Health

lapidot medical import and marketing ltd - paricalcitol - solution for injection - paricalcitol 5 mcg / 1 ml - paricalcitol - rextol 5 mcg/ml is indicated for the prevention and treatment of secondary hyperparathyrodism in patients with chronic renal failure who are undergoing haemodialysis.